We are live on ! Find out more
SYRS

Syros Pharmaceuticals, Inc. Common Stock
SYRS

Delisted

SYRS was delisted on the 19th of March, 2025.

Back to rankings

106 hedge funds and large institutions have $475M invested in Syros Pharmaceuticals, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 44 increasing their positions, 29 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

52% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 29

42% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 12

5% more funds holding

Funds holding: 101 → 106 (+5)

19% less capital invested

Capital invested by funds: $590M → $475M (-$115M)

50% less funds holding in top 10

Funds holding in top 10: 4 → 2 (-2)

58% less call options, than puts

Call options by funds: $1.32M | Put options by funds: $3.17M

Holders
106
Holders Change
+5
Holders Change %
+4.95%
% of All Funds
1.86%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.04%
New
17
Increased
44
Reduced
29
Closed
12
Calls
$1.32M
Puts
$3.17M
Net Calls
-$1.85M
Net Calls Change
-$2.25M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$24.7M
2
RCM
RA Capital Management
Massachusetts
+$9.35M
3
BlackRock
BlackRock
New York
+$8.75M
4
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group
Japan
+$8.15M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$7.14M

Top Sellers

Rank Fund Capital Flow
1
AIM
ARK Investment Management
Florida
-$13.8M
2
PCM
Portolan Capital Management
Massachusetts
-$4.14M
3
Millennium Management
Millennium Management
New York
-$2.2M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$2.04M
5
CIA
Capital Impact Advisors
Massachusetts
-$1.83M
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Advisers
26
Two Sigma Advisers
New York
$2.21M +$675K +6,500 +28%
RG
27
Redmile Group
California
$1.59M – – –
Two Sigma Investments
28
Two Sigma Investments
New York
$1.57M +$741K +7,135 +51%
Millennium Management
29
Millennium Management
New York
$1.26M -$2.2M -21,148 -56%
PP
30
PDT Partners
New York
$1.1M +$653K +6,289 +74%
Bank of New York Mellon
31
Bank of New York Mellon
New York
$1.1M +$117K +1,122 +8%
N
32
Nuveen
North Carolina
$1.1M +$22.9K +220 +2%
ACM
33
Altium Capital Management
New York
$948K +$1.32M +12,670 New
Alyeska Investment Group
34
Alyeska Investment Group
Illinois
$935K +$1.3M +12,500 New
AA
35
ALPS Advisors
Colorado
$834K +$299K +2,880 +35%
IC
36
Ikarian Capital
Texas
$748K – – –
Ensign Peak Advisors
37
Ensign Peak Advisors
Utah
$748K +$1.04M +10,000 New
Los Angeles Capital Management
38
Los Angeles Capital Management
California
$676K -$259K -2,495 -22%
Susquehanna International Group
39
Susquehanna International Group
Pennsylvania
$676K -$79.4K -764 -8%
California Public Employees Retirement System
40
California Public Employees Retirement System
California
$639K -$81.7K -786 -8%
State of Wisconsin Investment Board
41
State of Wisconsin Investment Board
Wisconsin
$624K -$65.5K -630 -7%
PAI
42
Palo Alto Investors
California
$603K +$837K +8,060 New
Barclays
43
Barclays
United Kingdom
$577K +$658K +6,330 +461%
Squarepoint
44
Squarepoint
New York
$566K +$481K +4,627 +157%
California State Teachers Retirement System (CalSTRS)
45
California State Teachers Retirement System (CalSTRS)
California
$532K +$86.4K +832 +13%
GCP
46
GSA Capital Partners
United Kingdom
$485K +$674K +6,483 New
QI
47
QS Investors
New York
$479K +$409K +3,940 +160%
Jacobs Levy Equity Management
48
Jacobs Levy Equity Management
New Jersey
$472K -$618K -5,949 -49%
Deutsche Bank
49
Deutsche Bank
Germany
$420K +$261K +2,513 +81%
RhumbLine Advisers
50
RhumbLine Advisers
Massachusetts
$349K -$8.1K -78 -2%
1
2
3 4 5

SYRS Hedge Fund Activity: Q1 2021 in Review

106 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Syros Pharmaceuticals, Inc. Common Stock (SYRS) for Q1 2021, worth a combined $475M — down 19% from $590M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new SYRS positions and 12 closed out — a net gain of 5 holders — while 44 added to existing stakes and 29 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $24.7M. The largest seller was ARK Investment Management, cutting an estimated $13.8M.

  • 106 institutional investors held Syros Pharmaceuticals, Inc. Common Stock (SYRS) as of Q1 2021, up from 101 in Q4 2020.
  • Funds reported $475M of Syros Pharmaceuticals, Inc. Common Stock stock for Q1 2021, down 19% quarter-over-quarter.
  • 17 funds opened new Syros Pharmaceuticals, Inc. Common Stock positions in Q1 2021 and 12 closed out, a net change of +5 holders.
  • The largest Syros Pharmaceuticals, Inc. Common Stock buyer in Q1 2021 was Fidelity Investments, an estimated $24.7M added.
  • The largest Syros Pharmaceuticals, Inc. Common Stock seller in Q1 2021 was ARK Investment Management, an estimated $13.8M sold.

Based on aggregated 13F filings for Q1 2021.